Protecting renal function in the hypertensive patient: Clinical guidelines

American Journal of Hypertension

Volumn 18, Issue 4 SUPPL., 2005, Pages 112-119

  Bakris, George L ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Amlodipine besylate; Benazepril hydrochloride; Chronic kidney disease; Hypertension; Renin angiotensin system

Indexed keywords

ACETYLSALICYLIC ACID; ALDOSTERONE ANTAGONIST; AMLODIPINE; AMLODIPINE PLUS BENAZEPRIL; ANGIOTENSIN ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BENAZEPRIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; HYDROCHLOROTHIAZIDE; LOOP DIURETIC AGENT; THIAZIDE DIURETIC AGENT;

BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONFERENCE PAPER; COST BENEFIT ANALYSIS; DISEASE CONTROL; GLUCOSE BLOOD LEVEL; HUMAN; HYPERKALEMIA; HYPERTENSION; INCIDENCE; KIDNEY FAILURE; KIDNEY FUNCTION; LIPID BLOOD LEVEL; MEASUREMENT; MORBIDITY; PATIENT; PREVALENCE; PRIORITY JOURNAL; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK FACTOR; UNITED STATES;

EID: 17444404947     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjhyper.2004.11.046     Document Type: Conference Paper

References (44)

1. U.S. Renal Data System USRDS 2003 Annual Data Report Atlas of End-Stage Renal Disease in the United States 2003 National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases Bethesda, MD
2. National Kidney Foundation K/DOQI clinical practice guidelines for chronic kidney disease evaluation, classification, and stratification Am J Kidney Dis 39 2002 S1 S266
3. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) JAMA 285 2001 2486 2497
4. S.M. Grundy, G.J. Balady, M.H. Criqui, G. Fletcher, P. Greenland, L.F. Hiratzka, N. Houston-Miller, P. Kris-Etherton, H.M. Krumholz, J. LaRosa, I.S. Ockene, T.A. Pearson, J. Reed, R. Washington, S.C. Smith Jr Primary prevention of coronary heart disease: guidance from Framingham. A statement for healthcare professionals from the AHA Task Force on Risk Reduction Circulation 97 1998 1876 1887
5. C.S. Fox, M.G. Larson, E.P. Leip, B. Culleton, P.W.F. Wilson, D. Levy Predictors of new-onset kidney disease in a community-based population JAMA 291 2004 844 850
6. E.M. Stuveling, S.J. Bakker, H.L. Hillege, J.G. Burgerhof, P.E. de Jong, R.O. Gans, D. de Zeeuw C-reactive protein modifies the relationship between blood pressure and microalbuminuria Hypertension 43 2004 791 795
7. American Diabetes Association Nephropathy in diabetes Diabetes Care 27 Suppl 1 2004 S79 S83
8. J.F.E. Mann, H.C. Gerstein, J. Pogue, J. Bosch, S. Yusuf HOPE Investigators Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril the HOPE randomized trial Ann Intern Med 134 2001 629 636
9. H.C. Gerstein, J.F. Mann, Q. Yi, B. Zinman, S.F. Dinneen, B. Hoogwerf, J.P. Hallé, J. Young, A. Rushkow, C. Joyce, S. Nawaz, S. Yusuf HOPE Study Investigators Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals JAMA 286 2001 421 426
10. H.L. Hillege, V. Fidler, G.F.H. Diercks, W.H. van Gilst, D. de Zeeuw, D.J. van Veldhuisen, R.O.B. Gans, W.M.T. Janssen, D.E. Grobbee, P.E. de Jong Prevention of Renal and Vascular End Stage Disease (PREVEND) Study Group Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population Circulation 106 2002 1777 1782
11. JNC 7 Express The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure National High Blood Pressure Education Program 2003 National Institutes of Health Bethesda, MD NIH Publication No. 03-5233.
12. L.E. Boulware, B.G. Jaar, M.E. Tarver-Carr, F.L. Brancati, N.R. Powe Screening for proteinuria in US adults a cost-effectiveness analysis JAMA 290 2003 3101 3114
13. J. Stamler, O. Vaccaro, J.D. Neaton, D. Wentworth Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial Diabetes Care 16 1993 434 444
14. M.J. Klag, P.K. Whelton, B.L. Randall, J.D. Neaton, F.L. Brancati, C.E. Ford, N.B. Shulman, J. Stamler Blood pressure and end-stage renal disease in men N Engl J Med 334 1996 13 18
15. B.M. Psaty, C.D. Furberg, L.H. Kuller, M. Cushman, P.J. Savage, D. Levine, D.H. O'Leary, R.N. Bryan, M. Anderson, T. Lumley Association between blood pressure level and the risk of myocardial infarction, stroke, and total mortality the cardiovascular health study Arch Intern Med 161 2001 1183 1192
16. R.S. Vasan, A. Beiser, S. Seshadri, M.G. Larson, W.B. Kannel, R.B. D'Agostino, D. Levy Residual lifetime risk for developing hypertension in middle-aged women and men the Framingham Heart Study JAMA 287 2002 1003 1010
17. S. Lewington, R. Clarke, N. Qizilbash, R. Peto, R. Collins Prospective Studies Collaboration Age-specific relevance of usual blood pressure to vascular mortality a meta-analysis of individual data for one million adults in 61 prospective studies Lancet 360 2002 1903 1913
18. G.L. Bakris, M. Williams, L. Dworkin, W.J. Elliott, M. Epstein, R. Toto, K. Tuttle, J. Douglas, W. Hsueh, J. Sowers National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group Preserving renal function in adults with hypertension and diabetes a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group Am J Kidney Dis 36 2000 646 661
19. UK Prospective Diabetes Study Group Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes UKPDS 38 BMJ 317 1998 703 713
20. L. Hansson, A. Zanchetti, S.G. Carruthers, B. Dahlöf, D. Elmfeldt, S. Julius, J. Ménard, K.H. Rahn, H. Wedel, S. Westerling Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension principal results of the Hypertension Optimal Treatment (HOT) randomised trial Lancet 351 1998 1755 1762
21. R.O. Estacio, R.W. Schrier Antihypertensive therapy in type 2 diabetes implications of the Appropriate Blood Pressure Control in Diabetes (ABCD) trial Am J Cardiol 82 1998 9R 14R
22. Effects of diet and antihypertensive therapy on creatinine clearance and serum creatinine concentration in the Modification of Diet in Renal Disease Study J Am Soc Nephrol 7 1996 556 566
23. S.S. Franklin, M.G. Larson, S.A. Khan, N.D. Wong, E.P. Leip, W.B. Kannel, D. Levy Does the relation of blood pressure to coronary heart disease risk change with aging? The Framingham Heart Study Circulation 103 2001 1245 1249
24. National Kidney Foundation K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease Am J Kidney Dis 43 Suppl 1 2004 S1 S290
25. T.H. Jafar, P.C. Stark, C.H. Schmid, M. Landa, G. Maschio, P.E. de Jong, D. de Zeeuw, S. Shahinfar, R. Toto, A.S. Levey AIPRD Study Group Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis Ann Intern Med 139 2003 244 252
26. K.C. Abbott, E. Basta, G.L. Bakris Blood pressure control and nephroprotection in diabetes J Clin Pharmacol 44 2004 431 438
27. J.G. Douglas, G.L. Bakris, M. Epstein, K.C. Ferdinand, J.M. Flack, K.A. Jamerson, W.E. Jones, J. Haywood, R. Maxey, E.O. Ofili, E. Saunders, E.L. Schiffrin, D.A. Sica, J.R. Sowers, D.G. Vidt Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks Management of high blood pressure in African Americans consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks Arch Intern Med 163 2003 525 541
28. American Diabetes Association Hypertension management in adults with diabetes Diabetes Care 27 2004 S65 S67
29. Heart Outcomes Prevention Evaluation Study Investigators Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus results of the HOPE study and MICRO-HOPE substudy Lancet 355 2000 253 259
30. E.J. Lewis, L.G. Hunsicker, R.P. Bain, R.D. Rohde Collaborative Study Group The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy N Engl J Med 329 1993 1456 1462
31. E.J. Lewis, L.G. Hunsicker, W.R. Clarke, T. Berl, M.A. Pohl, J.B. Lewis, E. Ritz, R.C. Atkins, R. Rohde, I. Raz Collaborative Study Group Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes N Engl J Med 345 2001 851 860
32. H.-H. Parving, H. Lehnert, J. Brochner-Mortensen, R. Gomis, S. Andersen, P. Arner Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes N Engl J Med 345 2001 870 878
33. B.M. Brenner, M.E. Cooper, D. de Zeeuw, W.F. Keane, W.E. Mitch, H.-H. Parving, G. Remuzzi, S.M. Snapinn, Z. Zhang, S. Shahinfar RENAAL Study Investigators Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy N Engl J Med 345 2001 861 869
34. GISEN group (Gruppo Italiano di Studi Epidemiologici in Nefrologia) Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal failure in proteinuric, non-diabetic nephropathy Lancet 349 1997 1857 1863
35. H.E. Lebovitz, T.B. Wiegmann, A. Cnaan, S. Shahinfar, D.A. Sica, V. Broadstone, S.L. Schwartz, M.C. Mengel, R. Segal, J.A. Versaggi Renal protective effects of enalapril in hypertensive NIDDM role of baseline albuminuria Kidney Int 45 Suppl 1994 S150 S155
36. J.T. Wright Jr, G. Bakris, T. Greene, T.L.Y. Agodoa, L.J. Appel, J. Charleston, D. Cheek, J.G. Douglas-Baltimore, J. Gassman, R. Glassock, L. Hebert, K. Jamerson, J. Lewis, R.A. Phillips, R.D. Toto, J.P. Middletown, S.G. Rostand African American Study of Kidney Disease and Hypertension Study Group Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease results from the AASK trial JAMA 288 2002 2421 2431
37. G. Maschio, D. Alberti, G. Janin, F. Locatelli, J.F.E. Mann, M. Motolese, C. Ponticelli, E. Ritz, P. Zucchelli Angiotensin-Converting-Enzyme Inhibition in the Progressive Renal Insufficiency Study Group Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency N Engl J Med 334 1996 939 945
38. M.S. Weinberg, N. Kaperonis, G.L. Bakris How high should an ACE inhibitor or angiotensin receptor blocker be dosed in patients with diabetic nephropathy? Curr Hypertens Rep 5 2003 418 425
39. R. Toto Angiotensin II subtype 1 receptor blockers and renal function Arch Intern Med 161 2001 1492 1499
40. Y. Lacourciere, L. Poirier Antihypertensive effects of two fixed-dose combinations of losartan and hydrochlorothiazide versus hydrochlorothiazide monotherapy in subjects with ambulatory systolic hypertension Am J Hypertens 16 2003 1036 1042
41. E. Malacco, S. Piazza, R. Carretta, S. Di Somma, A. Mugellini, F. Bertocchi, P. Palatini Comparison of benazepril-amlodipine and captopril-thiazide combinations in the management of mild-to-moderate hypertension Int J Clin Pharmacol Ther 40 2002 263 269
42. Y. Lacourciere, K. Martin Comparison of a fixed-dose combination of 40 mg telmisartan plus 12.5 hydrochlorothiazide with 40 mg telmisartan in the control of mild to moderate hypertension Am J Ther 9 2002 111 117
43. G.L. Bakris, M.R. Weir Study of Hypertension and the Efficacy of Lotrel in Diabetes (SHIELD) Investigators Achieving goal blood pressure in patients with type 2 diabetes conventional versus fixed-dose combination approaches J Clin Hypertens 5 2003 202 209
44. J.M. Neutel, D.H.G. Smith, M.A. Weber, D. Purkayastha, O.M. Nwose, L. Schofield, M. Gatlin Initial combination therapy in older patients with systolic hypertension results of the SELECT (Systolic Evaluation of Lotrel Efficacy and Comparative Therapies) study [abstract] Am J Hypertens 17 2004 183A Abstract P-409.